North American nuclear medicine market | Analysis of Worldwide Industry Trends and Opportunities

According to the new market research report "North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024", published by MarketsandMarkets™,The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.

Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108

The alpha emitters segment is expected to command the largest share of the therapeutic nuclear medicine market in 2019 :

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. In 2013, the FDA approved the first and only product for alpha emitters in the market, launched by Bayer AG under the name Xofigo (a Ra-223 dichloride molecule).

Thyroid application segment is expected to register the highest growth during the forecast period :

Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications segment is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108

The US accounted for the largest share of the nuclear medicine market in 2018 :

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Key Market Players :

Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).

Want Full Report? Inquire Here: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=1108The US accounted for the largest share of the nuclear medicine market in 2018

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Key Questions Addressed by the Report

• Which product segment will dominate the North American nuclear medicine market in the future?
• Which application segment will dominate the market in the future?
• Emerging countries offer immense opportunities for the growth and adoption of nuclear medicine; will this scenario continue in the coming five years?
• Where will technology advancements offered by various companies take the industry in the mid- to long-term?
• What are the upcoming products in the nuclear medicine market?

Thyroid application segment is expected to register the highest growth during the forecast period

Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications segment is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.